Literature DB >> 25500625

Fecal microbiota transplantation for gastrointestinal diseases.

Katsuyoshi Matsuoka1, Shinta Mizuno, Atsushi Hayashi, Tadakazu Hisamatsu, Makoto Naganuma, Takanori Kanai.   

Abstract

Fecal microbiota transplantation (FMT) is a treatment to restore the normal microbial composition of the gut by introducing fecal microbiota obtained from a healthy donor into a diseased individual. There has been a growing interest in the use of FMT as a treatment of various diseases including Clostridium difficile infection (CDI), inflammatory bowel disease, and irritable bowel syndrome. Despite the increasing application of FMT, there are no standard protocols. Many aspects of FMT procedures vary regarding donor selection, preparation of fecal materials, recipient preparation, and route of administration. FMT is most successful in treating recurrent CDI. A randomized controlled trial reported a success rate of approximaetly 90%. Ulcerative colitis (UC) is a potentially good indication for FMT, although limited evidence is available on the use of FMT for the treatment of UC. Only several small case series have been reported, and the results in terms of efficacy are inconsistent. FMT can also be used to treat diseases other than gastrointestinal disorders in which the gut microbiota is disturbed, e.g., cardiovascular diseases, autoimmune diseases, and metabolic disorders. There remain many unanswered questions with regard to FMT, and more research is required in this field.

Entities:  

Mesh:

Year:  2014        PMID: 25500625     DOI: 10.2302/kjm.2014-0006-RE

Source DB:  PubMed          Journal:  Keio J Med        ISSN: 0022-9717


  8 in total

Review 1.  A breakthrough in probiotics: Clostridium butyricum regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease.

Authors:  Takanori Kanai; Yohei Mikami; Atsushi Hayashi
Journal:  J Gastroenterol       Date:  2015-05-05       Impact factor: 7.527

2.  Fecal microbiota transplantation for recurrent Clostridium difficile infection in a patient with ulcerative colitis.

Authors:  Kosaku Nanki; Shinta Mizuno; Katsuyoshi Matsuoka; Keiko Ono; Shinya Sugimoto; Hiroki Kiyohara; Mari Arai; Moeko Nakashima; Kozue Takeshita; Keiichiro Saigusa; Mitsutoshi Senoh; Tadashi Fukuda; Makoto Naganuma; Haru Kato; Wataru Suda; Masahira Hattori; Takanori Kanai
Journal:  Intest Res       Date:  2018-01-18

3.  Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome.

Authors:  Shinta Mizuno; Tatsuhiro Masaoka; Makoto Naganuma; Taishiro Kishimoto; Momoko Kitazawa; Shunya Kurokawa; Moeko Nakashima; Kozue Takeshita; Wataru Suda; Masaru Mimura; Masahira Hattori; Takanori Kanai
Journal:  Digestion       Date:  2017-06-21       Impact factor: 3.216

Review 4.  Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives.

Authors:  Lie Zheng; Yong-Yi Ji; Xin-Li Wen; Sheng-Lei Duan
Journal:  World J Gastroenterol       Date:  2022-06-21       Impact factor: 5.374

5.  Free fatty acid receptor 3 activation suppresses neurogenic motility in rat proximal colon.

Authors:  I Kaji; Y Akiba; T Furuyama; D W Adelson; K Iwamoto; M Watanabe; A Kuwahara; J D Kaunitz
Journal:  Neurogastroenterol Motil       Date:  2017-07-17       Impact factor: 3.598

6.  Single fecal microbiota transplantation failed to change intestinal microbiota and had limited effectiveness against ulcerative colitis in Japanese patients.

Authors:  Shinta Mizuno; Kosaku Nanki; Katsuyoshi Matsuoka; Keiichiro Saigusa; Keiko Ono; Mari Arai; Shinya Sugimoto; Hiroki Kiyohara; Moeko Nakashima; Kozue Takeshita; Makoto Naganuma; Wataru Suda; Masahira Hattori; Takanori Kanai
Journal:  Intest Res       Date:  2017-01-31

7.  Understanding the Scope of Do-It-Yourself Fecal Microbiota Transplant.

Authors:  Chiazotam Ekekezie; Bryce K Perler; Anna Wexler; Catherine Duff; Christian John Lillis; Colleen R Kelly
Journal:  Am J Gastroenterol       Date:  2020-04       Impact factor: 12.045

8.  Describing the fecal metabolome in cryogenically collected samples from healthy participants.

Authors:  Kajetan Trošt; Linda Ahonen; Tommi Suvitaival; Nina Christiansen; Trine Nielsen; Maja Thiele; Suganya Jacobsen; Aleksander Krag; Peter Rossing; Torben Hansen; Lars Ove Dragsted; Cristina Legido-Quigley
Journal:  Sci Rep       Date:  2020-01-21       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.